Persistent URL of this record https://hdl.handle.net/1887/3766896
Documents
-
- Download
- Full text
- Publisher's Version
-
open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials
Background
Epstein–Barr virus positivity (EBV+) and microsatellite instability (MSI-high) are positive prognostic factors for survival in resectable gastric cancer (GC). However, benefit of perioperative treatment in patients with MSI-high tumors remains topic of discussion. Here, we present the clinicopathological outcomes of patients with EBV+, MSI-high, and EBV−/MSS GCs who received either surgery only or perioperative treatment.
Methods
EBV and MSI status were determined on tumor samples collected from 447 patients treated with surgery only in the D1/D2 trial, and from 451 patients treated perioperatively in the CRITICS trial. Results were correlated to histopathological response, morphological tumor characteristics, and survival.
Results
In the D1/D2 trial, 5-year cancer-related survival was 65.2% in 47 patients with EBV+, 56.7% in 47 patients with MSI-high, and 47.6% in 353 patients with EBV−/MSS tumors. In the CRITICS trial,...
Show moreBackground
Epstein–Barr virus positivity (EBV+) and microsatellite instability (MSI-high) are positive prognostic factors for survival in resectable gastric cancer (GC). However, benefit of perioperative treatment in patients with MSI-high tumors remains topic of discussion. Here, we present the clinicopathological outcomes of patients with EBV+, MSI-high, and EBV−/MSS GCs who received either surgery only or perioperative treatment.
Methods
EBV and MSI status were determined on tumor samples collected from 447 patients treated with surgery only in the D1/D2 trial, and from 451 patients treated perioperatively in the CRITICS trial. Results were correlated to histopathological response, morphological tumor characteristics, and survival.
Results
In the D1/D2 trial, 5-year cancer-related survival was 65.2% in 47 patients with EBV+, 56.7% in 47 patients with MSI-high, and 47.6% in 353 patients with EBV−/MSS tumors. In the CRITICS trial, 5-year cancer-related survival was 69.8% in 25 patients with EBV+, 51.7% in 27 patients with MSI-high, and 38.6% in 402 patients with EBV−/MSS tumors. Interestingly, all three MSI-high tumors with moderate to complete histopathological response (3/27, 11.1%) had substantial mucinous differentiation. No EBV+ tumors had a mucinous phenotype. 115/402 (28.6%) of EBV−/MSS tumors had moderate to complete histopathological response, of which 23/115 (20.0%) had a mucinous phenotype.
Conclusions
In resectable GC, MSI-high had favorable outcome compared to EBV−/MSS, both in patients treated with surgery only, and in those treated with perioperative chemo(radio)therapy. Substantial histopathological response was restricted to mucinous MSI-high tumors. The mucinous phenotype might be a relevant parameter in future clinical trials for MSI-high patients.
- All authors
- Biesma, H.D.; Soeratram, T.T.D.; Sikorska, K.; Caspers, I.A.; Essen, H.F. van; Egthuijsen, J.M.P.; Mookhoek, A.; Laarhoven, H.W.M. van; Henegouwen, M.I.V.; Nordsmark, M.; Peet, D.L. van der; Warmerdam, F.A.R.M.; Geenen, M.M.; Loosveld, O.J.L.; Portielje, J.E.A.; M. los; Heideman, D.A.M.; Kranenbarg, E.M.K.; Hartgrink, H.H.; Sandick, J. van; Verheij, M.; Velde, C.J.H. van de; Cats, A.; Ylstra, B.; Grieken, N.C.T. van
- Date
- 2022-02-07
- Journal
- Gastric Cancer
- Volume
- 25
- Issue
- 3
- Pages
- 640 - 651